My Treatment Approach: Improving Chronic Lymphocytic Leukemia Management and Treatment Outcomes - Episode 2
Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL
Bita Fakhri, MD, MPH, outlines factors she considers when choosing between fixed-duration and continuous BTK inhibitor therapy and discusses how she approaches treatment discussions with patients.
Video content above is prompted by the following question(s):
- What factors do you consider when choosing between fixed-duration and continuous BTK inhibitor therapy?
- How do you weigh the pros and cons of each approach, including treatment logistics and time off therapy?
- How do you weigh the pros and cons of each approach, including treatment logistics and time off therapy?
Related Content:
